Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
SomnoMed Ltd
SOMSomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. In addition, it provides Sunrise, a bio-signal to diagnose sleep apnea. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia. Address: 20 Clarke Street, Crows Nest, NSW, Australia, 2065
Analytics
Zielpreis von Wall Street
0.35 AUDKGV
–Dividendenrendite
–Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen SOM
Dividenden-Analyse SOM
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
–Verlauf der Dividende SOM
Bewertung der Aktie SOM
Finanzen SOM
Ergebnisse | 2019 | Dynamik |